Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Sarcoma 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 5Neoplasm Metastasis 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Small Cell Lung Carcinoma 2Neurofibrosarcoma 2Lung Neoplasms 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Dermatofibrosarcoma 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor - Protocol Specific 1Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Osteosarcoma 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Hypertension 1Histiocytoma 1

Interventions

pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Paraganglioma, Extra-Adrenal × pazopanib × Clear all
NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

National Cancer Institute (NCI)

Phase 2 Terminated
7 enrolled 8 charts
CNSEndocrine

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡